Adam M Boruchov MD

Hematologic Oncology, Myeloproliferative Disorder Hematology-Oncology

SVP, Chair of Cancer Institute, Nuvance Health Professor of Medicine, University of Connecticut SOM

21 Elm StNew Milford, CT 06776

Dr. Boruchov is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Boruchov's full profile Already have an account?

Summary

Dr. Adam Boruchov is an oncologist based in New Milford, CT, specializing in hematologic oncology. He completed his fellowship in Hematology and Medical Oncology at Memorial Sloan Kettering Cancer Center and his residency in Internal Medicine at New York Presbyterian Hospital. He holds multiple leadership positions, including Senior Vice President and Chair of the Cancer Institute at Nuvance Health. Dr. Boruchov is experienced in immunotherapy, hematologic oncology, clinical research, and immunology. He has authored several publications focused on leukemia, lymphoma, and myeloma, with some being cited multiple times. Additionally, he has been involved in clinical trials investigating treatments for conditions such as immune thrombocytopenic purpura and refractory lymphomas.

Education & Training

Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2000 - 2003
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1997 - 2000
State University of New York Downstate Medical Center College of MedicineClass of 1997

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

CT State Medical License 2008 - 2027
NY State Medical License 1998 - 2010
American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2016-2017
CMS Meaningful Use Stage 1 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2016-2017

Clinical Trials

Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma
COMPLETED
PHASE1, PHASE2
A Efficacy and Safety Study of R935788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP) Start of enrollment: 2014 Jul 14
COMPLETED
PHASE3

Publications & Presentations

PubMed

Long-term results of a phase 1/1b study of ibrutinib plus umbralisib for relapsed/refractory chronic lymphocytic leukemia.
Christine E Ryan, Yue Ren, Svitlana Tyekucheva, Jon E Arnason, Adam M Boruchov
Hemasphere. 2025-01-01
41 citations
Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma.
Romanos Sklavenitis-Pistofidis, Michelle P Aranha, Robert A Redd, Joanna Baginska, Nicholas J Haradhvala
Cancer Cell. 2022-11-14
24 citations
Romidepsin and lenalidomide-based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts
Neha Mehta-Shah, Matthew A. Lunning, Alison J. Moskowitz, Adam M. Boruchov, Jia Ruan
American Journal of Hematology. 2021-07-12

Lectures

Phase II Trial of Combination of Elotuzumab, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Yale Researchers Say Customized Cancer Vaccine Shows PromiseMay 20th, 2023
Study Shows That Immune System Holds Clues to Patients with High-Risk Smoldering Myeloma Likely to Benefit from TreatmentNovember 15th, 2022
Nuvance Health Appoints Adam Boruchov, MD, System Chair of the Cancer InstituteOctober 26th, 2023